"Abbott's Strong Q1 Performance Drives Stock Movement"
TL;DR Summary
Abbott reported first-quarter 2024 results with sales of $10.0 billion, driven by strong underlying base business performance and organic sales growth of 10.8 percent. The company raised the midpoint of its full-year guidance ranges for diluted EPS and organic sales growth, excluding COVID-19 testing-related sales. Abbott also highlighted the launch of new products and achievements in its nutrition, diagnostics, and medical devices segments. CEO Robert B. Ford expressed confidence in the company's performance, citing the fifth consecutive quarter of double-digit organic sales growth in the underlying base business.
- Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges Press Releases
- Abbott's robust medical device sales drive quarterly profit beat Yahoo Finance
- Abbott Labs Jumps, Retreats On Q1 Beat, Shy Guidance Investor's Business Daily
- Abbott's Diabetes Device Sales Drive Earnings Beat, Forecast Bloomberg
- Abbott Labs Stock Is Slipping After Earnings Beat. Here’s Why. Barron's
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
22 min
vs 23 min read
Condensed
98%
4,514 → 88 words
Want the full story? Read the original article
Read on Press Releases